Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite.
Schorlemmer
H U
HU
Research Laboratories, Hoechst Marion Roussel Deutschland GmbH, DG Rheumatology, Frankfurt, Germany. hansulrich.schorlemmer@hamrag.com
Kurrle
R
R
Schleyerbach
R
R
Bartlett
R R
RR
D000178:Acrylamides / Q000494:pharmacology*; D000480:Alkynes; D000818:Animals; D002208:Caproates / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005609:Free Radicals; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D016688:Mice, Inbred NOD; D009570:Nitriles; D013481:Superoxides / Q000378:metabolism*
D000178:Acrylamides; D000480:Alkynes; D002208:Caproates; D005609:Free Radicals; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D013481:Superoxides; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; C116406:HMR 1279